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Abstract
Background: Polypharmacy is an increasing problem, leading to increased morbidity and mortality, especially in
older, multimorbid patients. Consequently, there is a need for reduction of polypharmacy. The aim of this study was
to explore attitudes, beliefs, and concerns towards deprescribing among older, multimorbid patients with
polypharmacy who chose not to pursue at least one of their GP’s offers to deprescribe.
Methods: Exploratory study using telephone interviews among patients of a cluster-randomized study in Northern
Switzerland. The interview included a qualitative part consisting of questions in five pre-defined key areas of
attitudes, beliefs, and concerns about deprescribing and an open explorative question. The quantitative part
consisted of a rating of pre-defined statements in these areas.
Results: Twenty-two of 87 older, multimorbid patients with polypharmacy, to whom their GP offered a drug
change, did not pursue all offers. Nineteen of these 22 were interviewed by telephone. The 19 patients were on
average 76.9 (SD 10.0) years old, 74% female, and took 8.9 (SD 2.6) drugs per day. Drugs for acid-related disorders,
analgesics and anti-inflammatory drugs were the three most common drug groups where patient involvement and
the shared-decision-making (SDM) process led to the joint decision to not pursue the GPs offer. Eighteen of 19
patients fully trusted their GP, 17 of 19 participated in SDM even before this study and 8 of 19 perceived
polypharmacy as a substantial burden. Conservatism/inertia and fragmented medical care were the main barriers
towards deprescribing. No patient felt devalued as a consequence of the deprescribing offer. Our exploratory
findings were supported by patients’ ratings of predefined statements.
Conclusion: We identified patient involvement in deprescribing and coordination of care as key issues for
deprescribing among older multimorbid patients with polypharmacy. GPs concerns regarding patients’ devaluation
should not prevent them from actively discussing the reduction of drugs.
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Background
Polypharmacy (i.e. taking > 5 drugs/day) is an increasing
problem for multimorbid patients, in particular, older in-
dividuals [1–4]. If the drugs are used inappropriately, i.e.
with an inadequate ratio of benefit and harm or not meet-
ing patients’ needs [5, 6], polypharmacy leads to increased
morbidity, hospital admissions [7–9], health-related costs
[10] and mortality [5, 6, 11]. In Switzerland, 21% of all pa-
tients with polypharmacy were additionally affected by po-
tentially inappropriate medication according to lists by
Beers and Priscus [12–14]. Consequently, there is an on-
going call for deprescribing and several approaches to pur-
sue have been developed [15–21]. Approaches included
lists and criteria e.g. STOP/START criteria or the
EURO-FORTA (Fit fOR The Aged) list as well as elec-
tronic Decision Support (PRIMA-eDS) systems [20–22].
Despite encouraging results concerning the reduction of
drugs, findings concerning the impact of deprescribing on
clinical outcomes are variable. Especially implementation
of deprescribing into clinical practice remains a major
challenge. Attitudes, beliefs, and concerns resulting in in-
dividual barriers both on patients as well as general practi-
tioners (GPs) side have a major impact on how patients
respond to initiatives to deprescribe. [23–29]. For a suc-
cessful implementation, barriers such as understanding
(in) appropriateness of a drug, of the deprescribing
process or patient’s fear of withdrawal have to be taken
into account [26]. So far studies explored these barriers ei-
ther among patients not affected by deprescribing, while
studies among patients who actually chose not to pursue
an offer to deprescribe do not exist.
Thus the aim of our study was to explore barriers to-
wards deprescribing among older, multimorbid patients
with polypharmacy in Switzerland who did not pursue
their GPs offer. The results may help to optimize future
deprescribing initiatives.
Methods
Context and study setting
For this explorative study, we analyzed data from a
cluster-randomized study including 334 multimorbid pa-
tients (inclusion criteria: ≥ 60 years old, taking ≥5 drugs
per day) recruited by GPs in Northern Switzerland. This
study investigated the long-term effect of an algorithm
to reduce medication in comparison to usual care [16].
The algorithm included four questions the GP should
apply for each and every drug his patient received. Based
on this questions the GP had offer four alternatives for
each drug. Either to stop a drug, adjust its dosing or
substitute with an alternative or leave it unchanged. In a
SDM process the GP and the patient then decided
whether to pursue the GP’s offer or not. Details see Add-
itional file 1 for the algorithm used and Additional file 2
for actual case report form (CRF) used.
For the reporting, consolidated criteria for reporting
qualitative research (COREQ-reporting quidelines) were
used as appropriate [30], see details Additional file 3.
Definitions and study sample
We classified intervention group patients (patients exposed
to the deprescribing algorithm [16] as outlined in Fig. 1 into
a) offer group: patients having received an offer from
their GP to change at least one of their drugs
b) no-offer group: patients having received no offer
from their GP to change any of their drugs
Patients in the offer group were further classified into
a) pursuing group: patients pursuing their GP’s offer
b) non-pursuing group: patients choosing not pursue at
least one of their GP’s offers
Patients were eligible for the telephone interview if
classified in the “no pursue group”. Patients consent for
a potential telephone interview was obtained at baseline
of the main study, as well as patients’ characteristics
[16]. Qualitative and quantitative data were collected 1
month after the final consultation, i.e. 13 months after
patient’s study entry, by semi-structured telephone inter-
views. This time point was chosen to maintain blinding
during the main study’s follow-up of 12 months.
Interview guide development
Before conducting the interviews, we constructed an
interview guide as follows: First, we searched for factors
known to impact the deprescribing process in the litera-
ture [23–26, 29, 31–38] and summarized, simplified, and
adapted these findings and finally defined five key areas,
based on clinical relevance, by consensus within our study
group. The five key areas were trust/relationship between
patient and GP, involvement of the patient, conservatism/
inertia, burden of treatment and devaluation. For each key
area, we developed one or two questions to be rated by
the patient in regard to relevance for their decision. An
additional file shows the actual interview guide used for
this study (Additional file 2). We also added an open ex-
ploratory question in order to provide room for any new
insights from patients’ answers, related to key areas and
corresponding questions for the interview guide.
Finally, we tested the interview guide’s key areas and the
corresponding questions/statements in pilot interviews
until no more additional insights or new understandings
occurred. First, the interview guide was tested among two
members of institute staff not participating in this study
and secondly on two randomly assigned patients from the
main study. The latter data was not used for this study.
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Conduction of interviews and data collection
Between November 2016 and January 2017 a member of
the study group (SZ), already involved in the main study,
conducted one-to-one telephone interviews with pa-
tients in their homes, using the guide. SZ asked if they
were alone in the room and then introduced himself at
the beginning of the telephone contact and told each pa-
tient his working-position, explained reasons for this re-
search and reminded them of their participation in the
main study that ended a month ago. Additionally he
asked them to re-confirm their participation in the tele-
phone interview given initially at main study entry. In
case of non-response, telephone calls were repeated until
the patient was reached or reason for non-response was
clarified. Interviews lasted approximately 15 min, were
first transcribed verbatim on paper (ethics permission
for audio-recording was not sought for) and later trans-
ferred into the electronic database. No repeat interviews
were carried out nor were transcripts returned to inter-
viewees for correction or feedback on findings.
Data analysis
For content-analysis we used a thematic multi-stage pro-
cedure [36, 39–44]: First two researchers (SZ, CT) inde-
pendently summarized and coded patients’ answers until
saturation of codes was reached (Saturation was defined as
no new codes emerging any more in the course of analyz-
ing the interview transcripts). In a second step, we classified
Fig. 1 Inclusion flowchart: Of the 334 patients included in the original cluster-randomized study 19 were finally interviewed
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the previously coded answers into five predefined key areas.
In a third step, each researcher suggested potential new key
areas for these answers not fitting into the predefined areas.
In a fourth step, they checked for internal agreement and
discussed coding and potential new key areas The results
were then discussed within the entire study group and a de-
cision on new key areas was made. For the purpose of
reporting data, we post-hoc decided to collapse answers of
different questions once we realized patients gave answers
fitting key areas not specifically asked for in the according
question. Proportions derived from coding of patient an-
swers, taking into consideration all answers, independent of
the fact whether the answer was consistent with the specific
question or not. For example the meaning of 18/19 in the
case of trust and relationship implies that 18 out of 19 pa-
tients in this study had given at least one answer that was
coded into this key area by our researchers. We also added
a P for the patient and a number to allow alignment of
quotes to the individual patient.
We measured the frequencies of positive or negative
answers to questions corresponding with the key areas
and used a 5-point Likert scale (except question number
7 where we used a binary answer) for the statement rat-
ings. For descriptive analysis, we used numbers and per-
centages for categorical variables (Likert scale) and
means and standard deviation (SD) for continuous vari-
ables (patients’ characteristics). Data management and
all calculations were performed with database program
SecuTrial®, the database program SQL®, and the statistics
program R® [45–47].
Results
Twenty-two (25.3%) of 87 patients receiving an offer to
change drugs chose not to pursue at least one of their
GPs’ offers. Three out of these 22 dropped out due to
death (two patients) or cognitive decline (one patient)
making telephone interviews impossible. The mean age of
the remaining 19 patients, all of which agreed to partici-
pate was 76.9 (SD 10.0) years old, 12/19 (73.7%) were fe-
male (details see Fig. 1 and Table 1). They took a mean of
8.9 (SD 2.6) drugs and received offers to change for 68
drugs. Following the SDM-process the joint decision be-
tween GP and patient led to pursue 34 (50%) of these of-
fers while the other half was not pursued (like dose
changes). For details on drug groups patients actually
chose not to pursue their GPs’ offer see Additional file 4.
Table 1 According to data obtained from a
cluster-randomized study [16]. Quality of life: actual health
status using a Visual Analog Scale (VAS) ranging from 0
(worst imaginable) to 100 (best imaginable), Severity of
complaint using a VAS ranging from 0 (no complaint at all)
to 10 (unbearable). Drug pharmaceutical groups ranked by
frequency and restricted to the five most frequent groups.
Key areas
The five predefined key areas were trust/relationship be-
tween patient and GP, the involvement of the patient,
conservatism/inertia, burden of treatment and devalu-
ation. The following quotes provide more insight into
these areas.
Trust and relationship
18/19 patients reported to fully trust their GP.
“I fully trust my GP, he recommends what’s best for
me.” P1
“My GP is the best possible placebo, talking to him
helps me a lot.” P6
“He knows what’s important to me, he cares. He sees
more than the costs and effectiveness of drugs.” P8
“I would change my GP in case of lacking trust.” P11
“My GP discusses my medication with my caregivers, I
fully trust them.” P14
Table 1 Patient characteristics, in brackets unity of individual
characteristics
Characteristics
Patients (n) 19
Age (mean/SD) [years] 76.9 (10.0)
Female (n/%) 14 (73.7)
Weight (mean/SD) [kg] 76.5 (20.2)
Blood pressure (mean/SD) [mmHg]
Systolic 127.7 (8.3)
Diastolic 76.2 (11.2)
Hba1c (mean/SD) [%] 7.4 (0.6)
Drugs (mean/SD) 8.9 (2.6)
Quality of life (mean/SD) [0–100] 65.2 (17.1)
Severity of chief complaint (mean/SD) [0–10] 5.3 (2.4)
Living situation (n/%)
Living alone 4 (21.1)
Living with family 10 (52.6)
Living in a care center 5 (26.3)
Length of patient-GP relationship (mean/SD) [years] 10.4 (8.8)
Drugs not changed while recommended(n) 34
Drugs for acid related disorders (n/%) 8 (23.5)
Analgetics (n/%) 4 (11.2)
Anti-inflammatory and antirheumatics (n/%) 4 (11.2)
Psycholeptics (n/%) 3 (8.8)
Psychoanalgetics (n/%) 3 (8.8)
The content of the squared bracket specifies the unit used for the specific
characteristic
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Involvement
17/19 patients either had previous consultations focus-
ing on medication or wished for it. 10/19 patients had
no medication list. Six of these 10 patients wished for it.
“My GP informs me well, finally it is his turn to make
a decision. I do not understand it anyway”. P1
“I know my medication, but what happens in case of an
emergency? In that case, a medication list would be
perfect.” P3
“We discuss my medication-scheme regularly. My GP
knows what’s recommended, but in the end, I am the
only one who knows what’s good for me.” P9
Conservatism/inertia
15/19 patients felt that all of their drugs were necessary or
beneficial for their daily living. 9/19 mentioned the feeling
of security entailed with their drugs. 6/19 patients felt
deprescribing actually took away something which had been
beneficial for them in the past. None out of 19 patients did
regret their decision not to pursue their GP’s offer.
“I would love to reduce medication. Nevertheless, I
need the drugs my GP wanted to stop.” P3
“My answer is generally NO to changes in the first place.
I take new drugs only after reviewing information and
evaluation of non-drug alternatives.” P5
“I’d generally love to stop medication! But I need the
painkiller and proton pump inhibitor.” P8
“I have good experience with my drugs up to now, so
better not change the winning team.” P12
“I take my anti-acidity drug for almost 40 years – got
perfectly used to it.” P13
“I feel well now, obviously all of my drugs are needed.” P15
Burden of treatment
8/19 patients perceived that they were taking too many
drugs.
“There have been so many drug changes that I lost
track of the number. Anyway, the pharmacy packs
them daily.” P1
“First I didn’t like the fact, but now I accepted that I
need them.” P16
Devaluation
None out of 19 patients reported a feeling of worthless-
ness as a consequence of deprescribing offer. (Only one
patient reported that he had “somewhat” the feeling of
worthlessness, but not “to a great extend”).
New key area
6/19 patients mentioned as an answer in the add-
itional open question that the involvement of too
many different doctors was a problem for them. Ac-
cording to the procedure described in the method
section, we defined this topic as a new key area and
labeled it as “fragmented medical care” i.e. several
caregivers are in charge for the patient.
“Each and every doctor takes care of their medication
- almost one specialist for every drug.” P4
“I have got my GP for “real” medication and the
external team for alternative medication.” P16
Rating frequencies
Patients’ perception and rating for the predefined state-
ments are shown in Fig. 2. The statement number equals
the number in the interview guide. See (Additional file
2). Patients strongly approved that they had the feeling
their GP was caring (statements no. 5) and moderately
approved that they would like to participate more in the
decision-making process regarding drugs and would like
to have more consultations focusing on deprescribing
(statements no. 10 and no. 9) with approval rates of 94,
50, and 47% respectively. Patients rather disapproved
that they had the feeling something tried and true had
been taken away or they had a feeling of worthlessness
after the consultation (statement no. 3 and 4) with dis-
approval rates of 56 and 94%, respectively). Only one pa-
tient (6%) rather approved to the feeling of
worthlessness after the consultation, while the other 15
(94%) disapproved this feeling. 9 out of 19 patients had a
medication list, while the other 10 without list declared
that they would be interested in having one (question 7).
Discussion
When GPs offered to deprescribe, 22 of 87 of their older,
multimorbid patients chose not to pursue at least one of
their GPs offers following a SDM process. In this study,
we were able to interview 19 of those 22 patients. They
chose not to pursue to deprescribe, although a majority
of them fully trusted their GP and was already involved
in SDM before the study. About one third perceived
polypharmacy as a substantial burden. We found the fol-
lowing reasons for patients’ decision not to pursue their
GPs offer: 1) patients thought that they needed each
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drug; 2) patients felt deprescribing would remove some-
thing beneficial from them, and 3) too many physicians
were involved in medication management. Contrary to what
was expected from literature [18], no patient felt devalued
as a consequence of the deprescribing offer. The main find-
ings in the key areas trust and devaluation were supported
by patients’ ratings of predefined questionnaire statements,
while other key areas such as burden of treatment have
been approved to a lower degree in these ratings.
Trust is of utmost importance for a good patient-GP
relationship [33, 48], a prerequisite for a SDM process and
therefore most relevant for deprescribing procedures [49].
In our study, patients stated a high level of trust and a feel-
ing that their GP cared a lot. This is reflected in a long aver-
age duration of patient-physician-relationship as well.
Palagyi et al. reported that the willingness to change a drug
was strongly dependent on the GP as a central and trusted
person [33]. Nevertheless, high levels of trust did not
Fig. 2 Patients’ perception and rating of statements shows patients’ results rated on a 5-point Likert scale ranked according to patients’
perception as in question 1 and 8: from 1 = “Very bad” to 5 = “Very good”, and according to patients` rating of statements as in statement 2–5
and 9–10: from 1 = “Not at all” to 5 = “To a great extend”. Question 6 shows the number of patients stratified by their number of drugs taken
daily. Number 7 is not shown. The number at the beginning of each question respectively statement equals their number in the interview guide
(Additional file 2)
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encourage patients to accept all of their GPs’ offers to
change drugs in our study. Trust could even be an enabler
for choosing not to pursue the offer, as patients may feel
confident that their GPs are open-minded for listening to
their opinions and concerns. Thus, patients with a high level
of trust in their GPs even may feel encouraged not to pursue
the offer. A decision not to pursue the GP’s offer, is meeting
the spirit of SDM and therefore is a positive outcome [50].
The inconsistency between willingness to reduce drugs
combined with great trust in the GP on the one side and
the decision not to pursue the offer to do so on the
other side has been shown in literature before, although
not on such a large extent [51].
The lack of patient involvement and a low degree of
SDM were important barriers against deprescribing in
the review by Anderson et al. [24]. In our study sample,
all patients were involved in a SDM process due to the
type of study intervention and the majority reported to
have participated in a SDM process before the study and
were keen to participate again in the future. We con-
clude that a high level of patient involvement and SDM
does not necessarily mean that patients will pursue
deprescribing when offered by the GP. Similar to the
ambiguous role of trust, high levels of patient involve-
ment and SDM may empower patients to take a decision
along their own attitudes and concerns, which might not
be in line with their GP’s offer. Although potentially hin-
dering deprescribing, they are most valuable for a
patient-centered medicine. Thus the joint decision be-
tween GP and informed patient to continue a medica-
tion rather than pursuing an offer for deprescribing
could be the best decision for the patient if in line with
her/his values and preferences.
Conservatism and inertia were other important bar-
riers towards deprescribing mentioned by our patients,
as previously reported [24]. Potential reasons are the fear
of losing a beneficial drug effect, the fear of withdrawal
effects, as well as non-specific fears [24, 26, 51–53]. In
our study, the potential loss of a beneficial drug effect
matched with patients’ perception that they needed their
drugs for symptom relief. A closer look at the drug
groups where changes were not pursued showed that
the majority of these drugs had rather symptomatic than
prognostic effects (e.g. drugs for acid-related disorders,
analgesics or anti-inflammatory /antirheumatics). The
absence of symptoms at present may leave patients un-
clear whether this is indicating that a drug is no longer
needed, or a sign that the drug is successful, and there-
fore necessary [54, 55]. Thus, patients may keep a drug
rather than “taking risks” of a poor symptom control by
stopping. This fear of symptom increase may even out-
weigh the perceived burden of treatment reported by al-
most half of our patients. This concern of patients may
be best discussed openly during the deprescribing
encounter. Krol et al. reported a 24% reduction of pro-
ton pump inhibitors by critically addressing indication
and symptom relief [31]. Another approach may be
communicating to patients that continuing a drug may
be the greater risk than stopping it, due to interactions
or side effects. For this approach, physicians have to be
careful not to worry patients by this information.
Fragemented medical care as a barrier against depre-
scribing was mentioned by almost a third of our pa-
tients. This topic was reported in previous studies
mainly investigating GPs’ views, but not by patients until
now [25, 56, 57]. Patients feel uneasy to change a drug if
it has been prescribed by another health care provider,
which may be a kind of loyalty to this person. This bar-
rier could possibly be avoided by the coordination of
care, for example by a managed care approach as previ-
ously shown for potentially inappropriate medications
[10]. Other approaches include computer-assisted infor-
mation flow, access to expert advice, access to
non-pharmaceutical options, and enhanced communica-
tion between specialists and GPs [24].
Surprisingly devaluation was mentioned in the state-
ment ratings by one patient only, and never spontan-
eously. Previous studies reported that GPs are concerned
that patients may interpret deprescribing as a sign of be-
ing given up on, similar to difficult discussions on life ex-
pectancy [18, 24, 25, 56, 58]. As a conclusion from this
finding, GPs concerns regarding patients’ devaluation
should not prevent them from actively discussing the re-
duction of drugs.
Further barriers to deprescribing discussed previously
were poor insight or inertia of GPs, a low self-efficacy to
address the topic with patients and feasibility issues like
time constraints. Only lack of time (3/19) and missing
information on possible medication or non-medication
alternatives (2/19) was reported by a minority of our pa-
tients. Contrasting literature, cost issues or beliefs about
the appropriateness of a drug were never mentioned by
our patients [23, 34, 59, 60]. This might be owed to the
Swiss health care system where the majority of costs are
covered by insurance plans. Appropriateness might not
be an issue for these patients as they trust their GPs and
therefore did not question the rationale for their drugs.
Concerning enablers, the literature suggests the
provision of enough time dedicated to deprescribing, a
clear step by step plan how to change drugs and the op-
tion to restart the drug whenever necessary or required
by the patient [24, 26, 61]. Major influencers, potentially
enabling as well as hindering the acceptance of depre-
scribing among patients, are family members, peers, and
media, as well as the former experience of the patient
with the drug under discussion [16].
Although only half of our patients remembered to re-
ceive a medication list a majority of them declared a
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wish for it. This opens the room for further GPs activ-
ities to optimize future pre- and deprescribing.
Strengths
To our knowledge, this is the first qualitative study
among older, multimorbid patients with polypharmacy
who actively chose not to pursue the offer of their
GP to deprescribe. By this selection of patients who
were exposed to a deprescribing offer of their GP and
had experienced an own negative reaction to this
offer, we had the possibility to explore attitudes and
barriers towards deprescribing in a unique real-life
setting. Until now, studies investigated GPs or pa-
tients views (or care-givers views) concerning atti-
tudes and barriers against deprescribing rather in a
hypothetical way. We managed to interview the vast
majority (> 85%) of these specific patients. By using
an explorative (qualitative and quantitative) approach
were able to explore the complexity of the patient’s
experience of deprescribing from several perspectives.
Limitations
There are a number of limitations that should be consid-
ered when interpreting the results of our study.
First, there might be the recall bias due to the long la-
tency between the initial consultation and the interview
(13 months).
Second, there is a relatively small sample size of 19 pa-
tients, limiting the generalizability of our results [62].
Nevertheless, we think that for this specific setting of a
consultation dedicated to deprescribing the results of
this highly selected study population are of interest.
Third, although we conducted pilot interviews with
our interview guide, it was not systematically validated
in a separate study, thus limiting its applicability in fur-
ther studies.
Fourth, we are aware of the potential bias caused by
the fact that patients included in this study were previ-
ously selected to take part in a 12-months trial. A selec-
tion bias towards a generally fitter and better educated
population compared to patients not invited or declining
participation cannot be excluded. When interpreting
findings from this study one should keep in mind that
all clinical interactions between patients and GPs took
place within the larger context of a clinical trial.
Conclusion
We identified patient involvement in deprescribing
and coordination of care as key issues for deprescrib-
ing among older multimorbid patients with polyphar-
macy. GPs concerns regarding patients’ devaluation
should not prevent them from actively discussing the
reduction of drugs.
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main study. (GIF 21 kb)
Additional file 2: Interview guide. This file shows the interview guide
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indication group based on WHO ATC coding) [63]. (PDF 55 kb)
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